Quantcast

Latest Tyrosine-kinase inhibitor Stories

2014-10-14 16:28:33

WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its in-house developed agent lenvatinib mesylate (lenvatinib) as a treatment for progressive radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC) and granted the NDA Priority Review status. Priority Review designation occurs when the FDA believes the drug has the...

2014-09-03 08:34:35

FLINT, Mich., Sept. 3, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will be the exclusive distributor for SYNRIBO(®) (omacetaxine mepesuccinate) for subcutaneous injection intended for home use. On May 5, 2014, the U.S. Food and Drug Administration (FDA) expanded the indication of SYNRIBO(®) to allow for home administration. SYNRIBO(® )is a prescription medicine used to treat adult patients with chronic or accelerated phase...

2014-07-15 12:29:21

The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that, despite the fact that the treatment armamentarium for chronic myeloid leukemia (CML) in Brazil and Mexico includes all three tyrosine kinase inhibitors (TKIs)--Novartis' Glivec (imatinib), Bristol-Myers Squibb's Sprycel (dasatinib) and...

2014-06-02 12:28:29

High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed hematologists in China estimate that Novartis's Glivec (imatinib) will lose nearly half of its patient share for treatment of chronic myeloid leukemia (CML) in the next three years, due to the market entry of generic imatinib. Nevertheless,...

2014-05-27 12:32:14

Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/ -- Decision Resources Group finds that Novartis's Glivec is the clear agent of choice for first-line treatment of chronic myelogenous leukemia (CML) patients in the chronic phase, according to surveyed hematological oncologists from France, Germany, Italy, Spain and the United Kingdom (EU5). Use...

2014-05-23 16:23:48

FLINT, Mich., May 23, 2014 /PRNewswire-iReach/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will be distributing SYNRIBO(®) (omacetaxine mepesuccinate), now approved by the U.S. Food and Drug Administration for subcutaneous injection and home administration. SYNRIBO is a treatment for adults with chronic myeloid leukemia (CML) who are no longer responding to or are unable to tolerate two or more tyrosine kinase inhibitors (TKIs). The new...

2014-05-20 12:33:19

Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways. The trial is...

2014-04-29 12:27:59

Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists' are optimistic that Boehringer Ingelheim's second-generation irreversible EGFR tyrosine kinase inhibitor (TKI) Gilotrif/Giotrif will offer efficacy and delivery advantages over currently available agents for the second- and...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related